Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Plasswilm L, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Kaouthar K, Wust P, Thalmann GN, Aebersold DM. Ghadjar P, et al. Among authors: biaggi rudolf c. J Clin Oncol. 2015 Dec 10;33(35):4158-66. doi: 10.1200/JCO.2015.63.3529. Epub 2015 Nov 2. J Clin Oncol. 2015. PMID: 26527774 Clinical Trial.
Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
Ghadjar P, Hayoz S, Genitsch V, Zwahlen DR, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Stalder L, Biaggi-Rudolf C, Sumila M, Kranzbühler H, Najafi Y, Ost P, Azinwi NC, Reuter C, Bodis S, Khanfir K, Budach V, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK). Ghadjar P, et al. Among authors: biaggi rudolf c. BJU Int. 2017 Nov;120(5B):E45-E51. doi: 10.1111/bju.13742. Epub 2017 Jan 19. BJU Int. 2017. PMID: 27987524 Free article.
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK). Ghadjar P, et al. Among authors: biaggi rudolf c. Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3. Radiother Oncol. 2018. PMID: 29103826 Clinical Trial.
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Taverna C, et al. Among authors: biaggi rudolf c. J Clin Oncol. 2016 Feb 10;34(5):495-500. doi: 10.1200/JCO.2015.61.3968. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712227 Free PMC article. Clinical Trial.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Moccia AA, Taverna C, Schär S, Vanazzi A, Rondeau S, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Raats J, Rauch D, Vorobiof DA, Lohri A, Ruegsegger C, Biaggi Rudolf C, Rusterholz C, Hayoz S, Ghielmini M, Zucca E. Moccia AA, et al. Among authors: biaggi rudolf c. Blood Adv. 2020 Dec 8;4(23):5951-5957. doi: 10.1182/bloodadvances.2020002858. Blood Adv. 2020. PMID: 33275769 Free PMC article. Clinical Trial.
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Früh M, et al. Among authors: biaggi rudolf c. J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26. J Thorac Oncol. 2019. PMID: 30267838 Free article.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M, Froesch P, Eboulet EI, Addeo A, Pless M, Rothschild SI, Janthur WD, Burmeister H, Friedlaender A, Schneider M, Metaxas Y, Joerger M, Wannesson L, Schwitter M, Baudoux N, Weindler S, Biaggi-Rudolf C, Früh M; Swiss Group for Clinical Cancer Research (SAKK). Mark M, et al. Among authors: biaggi rudolf c. Cancer Immunol Immunother. 2021 May;70(5):1255-1262. doi: 10.1007/s00262-020-02757-8. Epub 2020 Nov 1. Cancer Immunol Immunother. 2021. PMID: 33130956 Free PMC article. Clinical Trial.
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y, Früh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R; Swiss Group for Clinical Cancer Research (SAKK). Metaxas Y, et al. Among authors: biaggi rudolf c. Ann Oncol. 2020 Apr;31(4):495-500. doi: 10.1016/j.annonc.2019.12.009. Epub 2020 Jan 16. Ann Oncol. 2020. PMID: 32085891 Free article. Clinical Trial.